| Code | CSB-RA839000MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to SL-325, targeting TNFRSF25 (Tumor Necrosis Factor Receptor Superfamily Member 25), also known as Death Receptor 3 (DR3). TNFRSF25 is a cell surface receptor that binds to its ligand TL1A and plays a critical role in regulating immune responses, particularly in T cell activation, proliferation, and differentiation. This receptor is predominantly expressed on lymphocytes and is involved in both pro-inflammatory and regulatory immune pathways. Dysregulation of the TNFRSF25/TL1A axis has been implicated in various autoimmune and inflammatory conditions, including inflammatory bowel disease, rheumatoid arthritis, and asthma, as well as in certain cancers where it may influence tumor immunity.
The reference antibody SL-325 has been utilized in research investigating TNFRSF25-mediated signaling pathways and its therapeutic potential in modulating immune responses. This biosimilar antibody serves as a valuable tool for researchers studying the molecular mechanisms of TNFRSF25 in immune regulation, inflammatory disease pathogenesis, and potential immunotherapeutic strategies.
There are currently no reviews for this product.